Education Pirtobrutinib Shows Promise as First-Line Treatment for CLL/SLL Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, has demonstrated significant potential as an initial therapy for patients with chronic lymphocytic leukemia (CLL) and... Editorial3 days ago